Abstract
Inhibition of growth stimulatory pathways has emerged as a major focus of targeted cancer drug development. New insights regarding potent, transient inhibition of cell signaling may challenge the dogma of medicinal chemistry and clinical trial design.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have